JP6445565B2 - とう痛及び糖尿病の治療用ナトリウムチャネル調節物質 - Google Patents

とう痛及び糖尿病の治療用ナトリウムチャネル調節物質 Download PDF

Info

Publication number
JP6445565B2
JP6445565B2 JP2016540921A JP2016540921A JP6445565B2 JP 6445565 B2 JP6445565 B2 JP 6445565B2 JP 2016540921 A JP2016540921 A JP 2016540921A JP 2016540921 A JP2016540921 A JP 2016540921A JP 6445565 B2 JP6445565 B2 JP 6445565B2
Authority
JP
Japan
Prior art keywords
chloro
compound
propyl
sulfamoyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016540921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016532716A5 (enExample
JP2016532716A (ja
Inventor
オルガ バビチ
オルガ バビチ
ティナ ギャリアンテス
ティナ ギャリアンテス
ロバート ズィー． ルオ
ロバート ズィー． ルオ
デイヴィッド ジェイ． パリング
デイヴィッド ジェイ． パリング
スリニヴァサン ピー． ヴェンカタチャラン
スリニヴァサン ピー． ヴェンカタチャラン
ヤンリン ワン−フィッシャー
ヤンリン ワン−フィッシャー
Original Assignee
クロモセル コーポレイション
クロモセル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クロモセル コーポレイション, クロモセル コーポレイション filed Critical クロモセル コーポレイション
Publication of JP2016532716A publication Critical patent/JP2016532716A/ja
Publication of JP2016532716A5 publication Critical patent/JP2016532716A5/ja
Application granted granted Critical
Publication of JP6445565B2 publication Critical patent/JP6445565B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2016540921A 2013-09-10 2014-09-09 とう痛及び糖尿病の治療用ナトリウムチャネル調節物質 Active JP6445565B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361876046P 2013-09-10 2013-09-10
US61/876,046 2013-09-10
PCT/US2014/054764 WO2015038533A2 (en) 2013-09-10 2014-09-09 Sodium channel modulators for the treatment of pain and diabetes

Publications (3)

Publication Number Publication Date
JP2016532716A JP2016532716A (ja) 2016-10-20
JP2016532716A5 JP2016532716A5 (enExample) 2017-10-19
JP6445565B2 true JP6445565B2 (ja) 2018-12-26

Family

ID=52666496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540921A Active JP6445565B2 (ja) 2013-09-10 2014-09-09 とう痛及び糖尿病の治療用ナトリウムチャネル調節物質

Country Status (18)

Country Link
US (2) US20160221974A1 (enExample)
EP (1) EP3043787B1 (enExample)
JP (1) JP6445565B2 (enExample)
KR (1) KR20160054570A (enExample)
CN (1) CN105611923B (enExample)
AU (1) AU2014318979B2 (enExample)
BR (1) BR112016005271A2 (enExample)
CA (1) CA2922851C (enExample)
ES (1) ES2687598T3 (enExample)
IL (1) IL244506B (enExample)
MX (1) MX2016002881A (enExample)
MY (1) MY181928A (enExample)
PH (1) PH12016500296A1 (enExample)
RU (1) RU2016113156A (enExample)
SG (2) SG10201805552PA (enExample)
UA (1) UA120353C2 (enExample)
WO (1) WO2015038533A2 (enExample)
ZA (1) ZA201702410B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022096A8 (pt) * 2013-03-15 2019-11-26 Chromocell Corp compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
CN105611923B (zh) 2013-09-10 2019-08-23 卓莫赛尔公司 用于治疗疼痛和糖尿病的钠通道调节剂
WO2016040315A1 (en) * 2014-09-09 2016-03-17 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes
TW201726637A (zh) 2015-12-18 2017-08-01 默沙東藥廠 對電位閘控鈉通道具選擇活性之羥基烷基胺－及羥基環烷基胺－取代之二胺－芳基磺胺化合物
KR102366077B1 (ko) 2016-05-20 2022-02-21 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
CN105924670A (zh) * 2016-06-02 2016-09-07 扬州兰都塑料科技有限公司 一种电力电缆用耐磨剂
CN105924843A (zh) * 2016-06-02 2016-09-07 扬州兰都塑料科技有限公司 一种耐刮擦的电力电缆
CN106084535A (zh) * 2016-06-02 2016-11-09 扬州兰都塑料科技有限公司 一种耐刮擦的电力电缆的制备方法
KR20190086772A (ko) 2016-12-09 2019-07-23 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
CN106892845B (zh) * 2017-02-28 2018-10-30 四川同晟生物医药有限公司 一种2,4-二氨基丁酸衍生物及其制备方法
WO2019200369A1 (en) * 2018-04-13 2019-10-17 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage
WO2019217822A1 (en) * 2018-05-11 2019-11-14 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions
BR112020024729A2 (pt) 2018-06-13 2021-03-23 Xenon Pharmaceuticals, Inc. compostos de benzenossulfonamida e seu uso como agentes terapêuticos
CA3104913A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
IL279810B2 (en) 2018-08-31 2025-03-01 Xenon Pharmaceuticals Inc Heteroaryl-modified sulfonamide compounds and their use as medicinal agents
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
ATE404568T1 (de) * 2001-03-14 2008-08-15 Gruenenthal Gmbh Substituierte thiazolopyrimidine als analgetika
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
WO2005054202A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
AU2005245386B2 (en) 2004-05-07 2008-11-27 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
AP2007003887A0 (en) * 2004-07-23 2007-02-28 Pfizer Pyridine derivatives
CA2584413A1 (en) 2004-10-29 2006-05-04 Astrazeneca Ab Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
DK1966130T3 (da) * 2005-12-23 2014-02-10 Zealand Pharma As Modificerede lysin-mimetiske forbindelser
JP2010518026A (ja) * 2007-02-05 2010-05-27 ゼノン・ファーマシューティカルズ・インコーポレイテッド ナトリウムチャネルが介在する疾患または状態の治療に有用なピリドピリミジノン化合物
CA2694748A1 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
HUE025013T2 (hu) * 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
CN105254557A (zh) 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
JP2013525368A (ja) 2010-04-23 2013-06-20 キネタ・インコーポレイテツド 抗ウイルス性化合物
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化学化合物
JP5860045B2 (ja) 2010-07-09 2016-02-16 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
CA2804593C (en) * 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
WO2012007883A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
JP2014507136A (ja) 2011-01-18 2014-03-27 アムジエン・インコーポレーテツド ＮａＶ１．７ノックアウトマウスとそれらの使用
TWI622583B (zh) * 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
AU2012296529A1 (en) 2011-08-17 2014-02-20 Amgen Inc. Heteroaryl sodium channel inhibitors
AU2012312266A1 (en) 2011-09-21 2013-05-02 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
EP2919770A4 (en) 2012-11-14 2017-03-08 The Board of Regents of The University of Texas System Inhibition of hif-2 heterodimerization with hif1 (arnt)
BR112015022096A8 (pt) * 2013-03-15 2019-11-26 Chromocell Corp compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
SG11201601616SA (en) 2013-09-09 2016-04-28 Peloton Therapeutics Inc Aryl ethers and uses thereof
CN105611923B (zh) 2013-09-10 2019-08-23 卓莫赛尔公司 用于治疗疼痛和糖尿病的钠通道调节剂
WO2016040315A1 (en) 2014-09-09 2016-03-17 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes

Also Published As

Publication number Publication date
IL244506A0 (en) 2016-04-21
ES2687598T3 (es) 2018-10-26
ZA201702410B (en) 2019-06-26
EP3043787B1 (en) 2018-09-05
US20160130239A1 (en) 2016-05-12
RU2016113156A3 (enExample) 2018-07-02
SG11201601367QA (en) 2016-03-30
BR112016005271A2 (pt) 2020-05-12
PH12016500296A1 (en) 2016-05-16
WO2015038533A2 (en) 2015-03-19
AU2014318979B2 (en) 2019-03-28
CN105611923A (zh) 2016-05-25
AU2014318979A1 (en) 2016-03-03
CA2922851A1 (en) 2015-03-19
US20160221974A1 (en) 2016-08-04
KR20160054570A (ko) 2016-05-16
CA2922851C (en) 2023-03-14
RU2016113156A (ru) 2017-10-16
EP3043787A2 (en) 2016-07-20
MX2016002881A (es) 2016-04-21
EP3043787A4 (en) 2017-02-01
UA120353C2 (uk) 2019-11-25
IL244506B (en) 2020-02-27
US9458118B2 (en) 2016-10-04
CN105611923B (zh) 2019-08-23
JP2016532716A (ja) 2016-10-20
SG10201805552PA (en) 2018-08-30
WO2015038533A3 (en) 2015-10-29
MY181928A (en) 2021-01-14

Similar Documents

Publication Publication Date Title
JP2016532716A (ja) とう痛及び糖尿病の治療用ナトリウムチャネル調節物質
JP6449845B2 (ja) 疼痛の処置のためのナトリウムチャネルモジュレーター
JPWO2011007819A1 (ja) ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
CN102958925A (zh) 吡唑衍生物钙释放激活钙通道调节剂及非小细胞肺癌的治疗方法
TW201018667A (en) Compounds for inflammation and immune-related uses
JP2017527573A (ja) 糖尿病の治療用の選択的ＮａＶ１．７阻害剤
CN110177782A (zh) RORγ调节剂及其用途
JP6483272B2 (ja) 白色脂肪組織の褐色化を誘導するための化合物および方法
TW202146381A (zh) 可用作RORγ調節劑的聯芳基類化合物
CA2853485A1 (en) Compounds for inflammation and immune-related uses
HK1224572A1 (en) Sodium channel modulators for the treatment of pain and diabetes
CA3163568A1 (en) Isoquinoline derivatives for use in treating glut1 deficiency syndrome
CN112745319A (zh) 一类取代三环结构的化合物、其制备方法及用途
JP2019529503A (ja) 置換フェニルプロピオン酸化合物のエナンチオマー及びその製造方法、、組成物並びに応用
WO2014077532A1 (ko) 신규한 피페라진 유도체, 이의 약학적으로 허용가능한 염 또는 이의 광학이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사질환 예방 또는 치료용 약학적 조성물
TW202423915A (zh) 抗炎化合物、藥物組合物以及治療血色病和其它疾患的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180515

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181015

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181129

R150 Certificate of patent or registration of utility model

Ref document number: 6445565

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250